Having trouble accessing articles? Reset your cache.

Emergent BioSolutions, Trubion deal

Emergent will acquire Trubion in a cash and stock deal that the companies said values Trubion at $4.55 per share, or $96.8 million. The price is a

Read the full 270 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE